Concepedia

Author

Vincent O’Neill

Sarah Cannon

Also Known As

Vincent J. O'Neill, Vincent J. O’Neill, Vincent O'Neill, Vincent O’Neill

38

Publications

2.3K

Citations

8

H-Index

15

Concepts

All Affiliations

Sarah CannonUCSF Helen Diller Family Comprehensive Cancer Center
VO

About

Vincent O’Neill is an author at Sarah Cannon specializing in prognostic biomarkers, tumor biology, and molecular diagnostic techniques.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

15

2

Cell Biology

1

1

15

3

Pathology

1

1

15

4

Cancer Genetics

1

1

15

5

Molecular Diagnostic Techniques

1

1

15

Vincent O’Neill

×

8

Publications

2.3K

Citations

8

H-Index

YearCitations

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad,

British Journal of Cancer

2020

850

Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard,

Clinical Cancer Research

2005

489

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Adam Brufsky, Sara A. Hurvitz, Edith A. Perez,

Journal of Clinical Oncology

2011

416

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Roy S. Herbst, Vincent O’Neill, Louis Fehrenbacher,

Journal of Clinical Oncology

2007

396

Fluorescence <i>In situ</i> Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Fred R. Hirsch, Marileila Varella‐Garcia, Rafał Dziadziuszko,

Clinical Cancer Research

2008

59

Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

David R. Spigel, Ming Lin, Vincent O’Neill,

Cancer

2008

27

Abstract 545: Plasma-based diagnostics for detection of EML4-ALK fusion transcripts in NSCLC patients

Kay Brinkmann, Daniel Enderle, Tina Koestler,

Cancer Research

2015

15

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Rahul Aggarwal, Jingsong Zhang, Xinhua Zhu,

Journal of Clinical Oncology

2023

13

Page 1